Timing of initial administration of low-molecular-weight heparin prophylaxis against deep vein thrombosis in patients following elective hip arthroplasty: A systematic review

Archives of Internal Medicine

Volumn 161, Issue 16, 2001, Pages 1952-1960

  Hull, Russell D ^a,b   Pineo, Graham F ^b   Stein, Paul D ⁱ   Mah, Andrew F ⁱ   MacIsaac, Susan M ⁱ   Dahl, Ola E ^d   Ghali, William A ^c   Butcher, Matthew S ⁱ   Brant, Rollin F ^b   Bergqvist, David ^e   Hamulyák, Karly ^f   Francis, Charles W ⁱ   Marder, Victor J ^g   Raskob, Gary E ^h  

^a FOOTHILLS HOSPITAL   (Canada)

^b UNIVERSITY OF CALGARY   (Canada)

^c UNIVERSITY OF CALGARY   (Canada)

^d ULLEVÅL UNIVERSITY HOSPITAL   (Norway)

^e UPPSALA UNIVERSITY   (Sweden)

^f MAASTRICHT UNIVERSITY MEDICAL CENTER   (Netherlands)

^g UNIVERSITY OF CALIFORNIA   (United States)

^h UNIVERSITY OF OKLAHOMA HEALTH SCIENCES CENTER   (United States)

ⁱ NONE

Author keywords

[No Author keywords available]

Indexed keywords

ACENOCOUMAROL; DALTEPARIN; LOW MOLECULAR WEIGHT HEPARIN; NADROPARIN; TINZAPARIN; WARFARIN; ANTICOAGULANT AGENT;

ANTICOAGULANT THERAPY; BLEEDING; CHRONOLOGY; CLINICAL TRIAL; DEEP VEIN THROMBOSIS; DRUG EFFICACY; DRUG SAFETY; HUMAN; POSTOPERATIVE COMPLICATION; PRIORITY JOURNAL; REVIEW; TOTAL HIP PROSTHESIS; ADULT; AGED; ANTICOAGULATION; DATA ANALYSIS; DRUG EFFECT; ELECTIVE SURGERY; EVALUATION; FEMALE; HIP ARTHROPLASTY; MALE; MEDICAL INFORMATION; MEDICAL LITERATURE; PHLEBOGRAPHY; POSTOPERATIVE PERIOD; RISK ASSESSMENT; RISK FACTOR; TIME;

EID: 0035955915     PISSN: 00039926     EISSN: None     Source Type: Journal    
DOI: 10.1001/archinte.161.16.1952     Document Type: Review

References (59)

1. A population-based perspective of the hospital incidence and case-fatality rates of deep vein thrombosis and pulmonary embolism
2. The prevalence of risk factors for venous thromboembolism among hospital patients
3. A prospective study of the incidence of deep-vein thrombosis within a defined urban population
4. Prevention of venous thromboembolism
5. Prevention of venous thromboembolism
6. Prevention of venous thromboembolism: International Consensus Statement
7. A randomized controlled trial of a low-molecular-weight heparin (enoxaparin) to prevent deep-vein thrombosis in patients undergoing elective hip surgery
8. Prevention of post-operative venous thrombosis: A randomized trial comparing unfractionated heparin with low molecular weight heparin in patients undergoing total hip replacement thrombosis and haemostasis
9. Low-molecular weight heparin (enoxaparin) vs dextran 70: The prevention of post-operative deep vein thrombosis after total hip replacement
10. Prevention of thromboembolism in 190 hip arthroplasties
11. Prevention of deep vein thrombosis and pulmonary embolism after total hip replacement
12. Prevention of deep vein thrombosis after elective hip surgery: A randomized trial comparing low molecular weight heparin with standard unfractionated heparin
13. Prevention of deep vein thrombosis after hip replacement: Randomized comparison between unfractionated heparin and low molecular weight heparin
14. Prevention of deep vein thrombosis after total hip replacement: The effect of low-molecular-weight heparin with spinal and general anaesthesia
15. Thromboprophylaxis by low-molecular-weight heparin in elective hip surgery: A placebo controlled study
16. Prevention of deep vein thrombosis with low molecular-weight heparin in patients undergoing total hip replacement: A randomized trial
17. A comparison of subcutaneous low-molecular-weight heparin with warfarin sodium for prophylaxis against deep-vein thrombosis after hip or knee implantation
18. Comparison of antithrombotic efficacy and haemorrhagic side effects of Clivarin versus enoxaparin in patients undergoing total hip replacement surgery
19. Efficacy and safety of enoxaparin to prevent deep venous thrombosis after hip replacement surgery
20. Use of enoxaparin, a low-molecular-weight heparin, and unfractionated heparin for the prevention of deep venous thrombosis after elective hip replacement: A clinical trial comparing efficacy and safety
21. Subcutaneous low-molecular-weight heparin or oral anticoagulants for the prevention of deep-vein thrombosis in elective hip and knee replacement?
22. Low-molecular-weight heparin (enoxaparin) as prophylaxis against venous thromboembolism after total hip replacement
23. Risk of deep-venous thrombosis after hospital discharge in patients having undergone total hip replacement: Double-blind randomized comparison of enoxaparin versus placebo
24. Prolonged thromboprophylaxis following hip replacement surgery: Results of a double-blind prospective, randomized, placebo-controlled study with dalteparin (Fragmin)
25. Prevention of deep-vein thrombosis after total hip arthroplasty: Comparison of warfarin and dalteparin
26. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
27. Low molecular weight heparin associated with spinal anaesthesia and gradual compression stockings in total hip replacement surgery
28. Efficacy and safety of prolonged thromboprophylaxis with a low-molecular-weight heparin (dalteparin) after total hip-arthroplasty: The Danish Prolonged Prophylaxis (DaPP) study
29. Prevent(on of deep vein thrombosis after total hip replacement: Comparison between two low-molecular-weight heparins, tinzaparin and enoxaparin
30. Prevention of fatal post-operative thromboembolism by heparin prophylaxis
31. The role of bone traumatization in the initiation of proximal deep vein thrombosis during cemented hip replacement surgery in pigs
32. Small subcutaneous doses of heparin in prevention of venous thrombosis
33. Starting prophylaxis for venous thromboembolism postoperatively
34. Low-molecular-weight heparin prophylaxis using dalteparin in close proximity to surgery vs warfarin in hip arthroplasty patients: A double-blind, randomized comparison
35. The medical review article revisited: Has the science improved?
36. Empirical evidence of bias: Dimensions of methodological quality associated with estimates of treatment effects in controlled trials
37. Quantitative synthesis in systematic reviews
38. Metan: An alternative meta-analysis command
39. Comparison of enoxaparin and warfarin for the prevention of venous thromboembolic disease after total hip arthroplasty: Evaluation during hospitalization and three months after discharge
40. RD heparin compared with warfarin for prevention of venous thromboembolic disease following total hip or knee arthroplasty
41. Low-molecular-weight heparin prophylaxis using dalteparin extended out-of-hospital vs in-hospital warfarin/out-of-hospital placebo in hip arthroplasty patients: A double-blind, randomized comparison
42. Preoperative vs post-operative initiation of low-molecular-weight heparin prophylaxis against venous thromboembolism in patients undergoing elective hip replacement
43. Two-step warfarin therapy: Prevention of post-operative venous thrombosis without excessive bleeding
44. Comparison of warfarin and external pneumatic compression in prevention of venous thrombosis after hip replacement
45. Comparison of two warfarin regimens in the prevention of venous thrombosis following total knee replacement
46. A comparison of recombinant hirudin with a low-molecular-weight heparin to prevent thromboembolic complications after total hip replacement
47. The EPHESUS Study: Comparison of the first synthetic factor Xa inhibitor with low-molecular-weight heparin (LMWH) in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
48. The Pentathlon 2000 study: Comparison of the first synthetic factor Xa inhibitor with low-molecular-weight heparin in the prevention of venous thromboembolism (VTE) after elective hip replacement surgery
49. Small doses of subcutaneous sodium heparin in preventing deep venous thrombosis after major sugery
50. Efficacy of low doses of heparin in prevention of deepvein thrombosis after major surgery: A double-blind, randomized trial
51. Prevention of fatal post-operative pulmonary embolism by low doses of heparin: An international multicentre trial
52. Prevention of venous thrombosis with small, subcutaneous doses of heparin
53. Prevention of venous thromboembolism in general surgical patients
54. FDA alert: FDA public health advisory
55. Low molecular weight heparin: Biochemistry, pharmacology, perioperative prophylaxis regimens and guidelines for regional anesthetic management
56. Thromboembolism and thromboprophylaxis in high-risk surgery: Facts and assumptions-a topic for emotions?
57. Neuraxial block and low-molecular-weight heparin: Balancing perioperative analgesia and thromboprophylaxis